LEUKOSCAN Powder for solution for injection Ref.[27586] Active ingredients: Technetium ⁹⁹ᵐTc sulesomab

Source: European Medicines Agency (EU)  Revision Year: 2018  Publisher: Immunomedics GmbH, Otto-Röhm-Straße 69, D-64293 Darmstadt, Germany

4.3. Contraindications

Patients with known allergies or hypersensitivity to mouse proteins.

Pregnancy.

4.4. Special warnings and precautions for use

Safety and diagnostic accuracy in persons under 21 years of age have not been established. Administration of LeukoScan to young subjects should only be performed after consideration of the possible risks and benefits to the individual subject.

Recommended imaging protocol

Immunoscintigraphy should be performed one to eight hours after injection.

There was essentially no difference in the detection of the presence or absence of osteomyelitis between the 1-2 hour timepoint and the 5-8 hour timepoint after injection. This suggests that imaging can be accomplished anytime between one and eight hours after injection (at the convenience of the nuclear medicine department and the patient).

Planar imaging in all views necessary to adequately visualise the affected area at 1-8 h post-injection with at least 500 k counts or ten minutes per view should be made. Image acquisition in analogue and/or digital word-mode and at least a 128 × 128 matrix is recommended.

Single photon emission computed tomography (SPECT) imaging can also be conducted and may aid in differentiating osteomyelitis from soft tissue infections. SPECT acquisition parameters recommended are: 60 projections in a 360° step-and-shoot technique, 30 seconds per view in at least a 64 × 64 matrix. Data processing by filtered backprojection and reconstruction in three planes (transaxial, coronal, and sagittal) is recommended.

Interpretation of the images

When a bone scan is positive and imaging with LeukoScan is negative, infection is unlikely.

When a bone scan is negative, imaging with LeukoScan may rarely show a positive response and this may indicate early osteomyelitis.

Hypersensitivity

Anaphylactic and other hypersensitivity reactions are possible whenever mouse protein materials are administered to patients. Appropriate cardiopulmonary resuscitation facilities and trained personnel should be available for immediate use in the event of an adverse reaction.

Human Anti-mouse Antibody (HAMA)

In clinical trials involving over 350 patients, no induction of human anti-mouse antibody (HAMA) to antibody fragments has been observed nor has there been any elevation of HAMA levels in patients with pre-existing HAMA.

Patients who have previously received murine monoclonal antibody products are more likely to have HAMA. In subjects with HAMA, there may be a greater chance of hypersensitivity reactions and diminished efficacy in imaging.

Readministration

There are, as yet, limited data on safety following repeated use. Readministration should only be considered in patients whose sera are negative for human anti-mouse antibody (HAMA) elevation in the fragment assay. The overall radiation dose received by the patient over time should also be taken into account.

HAMA titers should be determined before repeated administration of LeukoScan.

Paroxysmal nocturnal hemoglobinuria

LeukoScan is not expected to bind to leukocytes in patients with paroxysmal nocturnal hemoglobinuria.

4.5. Interaction with other medicinal products and other forms of interaction

Formal drug interaction studies have not been performed, but no drug interactions have been described to date, including patients receiving antibiotics.

4.6. Pregnancy and lactation

Women of childbearing potential

When it is necessary to administer radioactive medicinal products to women of childbearing potential, information should always be sought about pregnancy. Any woman who has missed a period should be assumed to be pregnant until proven otherwise. Where uncertainty exists, it is important that radiation exposure should be the minimum consistent with achieving the desired clinical information. Alternative techniques which do not involve ionising radiation should be considered.

Pregnancy

LeukoScan is contraindicated in pregnancy.

Radionuclide procedures carried out on pregnant women also involve radiation doses to the foetus. LeukoScan is contraindicated in pregnancy. Administration of 750 MBq LeukoScan will give an estimated absorbed dose of 4.1 mGy to an embryo or fetus at an early stage.

Lactation

Before administering a radioactive medicinal product to a mother who is breast feeding, consideration should be given as to whether the investigation could be reasonably delayed until the mother has ceased breast feeding and as to whether the most appropriate choice of radiopharmaceutical has been made, bearing in mind the secretion of activity in breast milk. If the administration is considered necessary, breast feeding should be interrupted and the expressed feeds discarded. It is usual to advise that breast feeding can be restarted when the level in the milk will not result in a radiation dose to the child greater than 1 mSv. Due to the short six-hour, half-life of 99mTc, a dose of less than 1 mSv in mother’s milk can be expected 24 hours after the administration of LeukoScan [99mTc].

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8. Undesirable effects

The following minor, self-limiting, rare adverse events were reported in the clinical trials and considered at least possibly related to LeukoScan: eosinophilia (3); and facial rash (1). None of these were considered serious, and all resolved without sequelae.

Post-marketing experience currently comprises greater than 70,000 vials sold, with two reports of selflimiting allergic reactions.

1. Statistically significant reductions in white blood cell (WBC) count were observed in the controlled studies at 24 hours post-injection, from a mean value of 8.9 to a mean value of 8.0 (× 103/mm³), but remained within the normal range, and returned to their pre-injection values by the time of the next measurement at 10 days. By contrast, in non-infected subjects, transient increases in WBC count were seen 24 hours after LeukoScan administration. The eosinophil count increased from 2.7% preinjection to 2.9% at 24 hours post-injection, and to 3.9% at 10 days, with the magnitude of both increases being statistically significant. The magnitude of these increases were assessed by the investigators to be of no clinical consequence on an individual patient basis.

It is unknown whether the changes in WBC or eosinophil counts observed, although of no clinical significance, are due to a transient effect on WBC function. If so, no inferences concerning the underlying mechanism(s) responsible may be derived from the clinical laboratory results. However, in vitro granulocyte function tests did not show significant changes when the sulesomab was added.

In vitro, a positive binding to lymphocytes up to 2-6% has been shown. The effect on lymphocyte function has not been determined.

2. HAMA:

No induction of human anti-mouse antibody (HAMA) reactive with fragment was observed in any patient administered LeukoScan.

3. For each patient, exposure to ionising radiation must be justifiable on the basis of likely benefit. The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic result. Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. For diagnostic nuclear medicine investigations, the current evidence suggests that the adverse effects will occur with low frequency because of the low radiation doses incurred.

4. For most diagnostic investigations using a nuclear medicine procedure, the radiation dose delivered (effective dose/EDE) is less than 20 mSv. Higher doses may be justified in some clinical circumstances.

6.2. Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in 6.6 or 12.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.